| Jyothi P Rao, MD | |
|
10207 Cerny St Ste 306, Raleigh, NC 27617-4887 | |
| (919) 684-3600 | |
| (919) 660-9201 |
| Full Name | Jyothi P Rao |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 27 Years |
| Location | 10207 Cerny St Ste 306, Raleigh, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699734533 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Duke Health Raleigh Hospital | Raleigh, NC | Hospital |
| Duke Regional Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
If Democrats fail to pass health legislation, the loss could have lasting consequences for a president whose supporters have become accustomed to victory, Time writes. "If the President fails to win the upcoming series of congressional votes designed to get health care legislation to his desk, it will be a calamitous failure for his presidency and for him personally, dwarfing the potholes he has hit during his first bumpy year in office.
Ethicists from Carnegie Mellon and McGill universities are calling on the global research community to resist treating the urgency of the current COVID-19 outbreak as grounds for making exceptions to rigorous research standards in pursuit of treatments and vaccines.
One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.
Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform.
› Verified 1 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
If Democrats fail to pass health legislation, the loss could have lasting consequences for a president whose supporters have become accustomed to victory, Time writes. "If the President fails to win the upcoming series of congressional votes designed to get health care legislation to his desk, it will be a calamitous failure for his presidency and for him personally, dwarfing the potholes he has hit during his first bumpy year in office.
Ethicists from Carnegie Mellon and McGill universities are calling on the global research community to resist treating the urgency of the current COVID-19 outbreak as grounds for making exceptions to rigorous research standards in pursuit of treatments and vaccines.
One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.
Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform.
› Verified 1 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
If Democrats fail to pass health legislation, the loss could have lasting consequences for a president whose supporters have become accustomed to victory, Time writes. "If the President fails to win the upcoming series of congressional votes designed to get health care legislation to his desk, it will be a calamitous failure for his presidency and for him personally, dwarfing the potholes he has hit during his first bumpy year in office.
Ethicists from Carnegie Mellon and McGill universities are calling on the global research community to resist treating the urgency of the current COVID-19 outbreak as grounds for making exceptions to rigorous research standards in pursuit of treatments and vaccines.
One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.
Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jyothi P Rao, MD 10207 Cerny St Ste 306, Raleigh, NC 27617-4887 Ph: (919) 684-3600 | Jyothi P Rao, MD 10207 Cerny St Ste 306, Raleigh, NC 27617-4887 Ph: (919) 684-3600 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
If Democrats fail to pass health legislation, the loss could have lasting consequences for a president whose supporters have become accustomed to victory, Time writes. "If the President fails to win the upcoming series of congressional votes designed to get health care legislation to his desk, it will be a calamitous failure for his presidency and for him personally, dwarfing the potholes he has hit during his first bumpy year in office.
Ethicists from Carnegie Mellon and McGill universities are calling on the global research community to resist treating the urgency of the current COVID-19 outbreak as grounds for making exceptions to rigorous research standards in pursuit of treatments and vaccines.
One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.
Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform.
› Verified 1 days ago
Dr. William Brooks Hall, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2605 Blue Ridge Rd Ste 190, Raleigh, NC 27607 Phone: 919-784-7460 | |
Dr. Serdal Aktolga, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3000 New Bern Ave, Raleigh, NC 27610 Phone: 919-350-8000 Fax: 919-350-7204 | |
Sheila A Munday, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3101 John Humphries Wynd, Raleigh, NC 27612 Phone: 919-881-8272 Fax: 919-881-2026 | |
Dr. James Robert Foster, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3000 New Bern Ave, G-100, Raleigh, NC 27610 Phone: 919-231-8253 Fax: 919-231-9546 | |
Dr. Michael Joseph Casey, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3604 Bush St, 2nd Floor, Raleigh, NC 27609 Phone: 919-876-7807 Fax: 919-876-8823 | |
Adnan Pervez, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2605 Blue Ridge Rd Ste 190, Raleigh, NC 27607 Phone: 919-784-7460 Fax: 919-784-5698 | |
Dr. Morgan Eileen Mullaney, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4420 Lake Boone Trl Ste 420, Raleigh, NC 27607 Phone: 919-784-3100 |